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Abstract
Introduction
There is a notable absence of consensus on how to generate estimates of population-level
incidence. Incidence is a considerably more sensitive indicator of epidemiological trends
than prevalence, but is harder to estimate. We used a novel hybrid method to estimate HIV
incidence by age and sex in a rural district of KwaZulu-Natal, South Africa.
Methods
Our novel method uses an ‘optimal weighting’ of estimates based on an implementation of a
particular ‘synthetic cohort’ approach (interpreting the age/time structure of prevalence, in
conjunction with estimates of excess mortality) and biomarkers of ‘recent infection’ (combin-
ing Lag-Avidity, Bio-Rad Avidity and viral load results to define recent infection, and adapting
the method for age-specific incidence estimation). Data were obtained from a population-
based cross-sectional HIV survey conducted in Mbongolwane and Eshowe health service
areas in 2013.
Results
Using the combined method, we find that age-specific HIV incidence in females rose rapidly
during adolescence, from 1.33 cases/100 person-years (95% CI: 0.98,1.67) at age 15 to a
peak of 5.01/100PY (4.14,5.87) at age 23. In males, incidence was lower, 0.34/100PY
(0.00-0.74) at age 15, and rose later, peaking at 3.86/100PY (2.52-5.20) at age 30. Suscep-
tible population-weighted average incidence in females aged 15-29 was estimated at
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3.84/100PY (3.36-4.40), in males aged 15-29 at 1.28/100PY (0.68-1.50) and in all individu-
als aged 15-29 at 2.55/100PY (2.09-2.76). Using the conventional recency biomarker
approach, we estimated HIV incidence among females aged 15-29 at 2.99/100PY (1.79-
4.36), among males aged 15-29 at 0.87/100PY (0.22-1.60) and among all individuals aged
15-59 at 1.66/100PY (1.13-2.27).
Discussion
HIV incidence was very high in women aged 15-30, peaking in the early 20s. Men had lower
incidence, which peaked at age 30. The estimates obtained from the hybrid method are
more informative than those produced by conventional analysis of biomarker data, and rep-
resents a more optimal use of available data than either the age-continuous biomarker or
synthetic cohort methods alone. The method is mainly useful at younger ages, where
excess mortality is low and uncertainty in the synthetic cohort estimates is reasonably small.
Conclusion
Application of this method to large-scale population-based HIV prevalence surveys is likely
to result in improved incidence surveillance over methods currently in wide use. Reasonably
accurate and precise age-specific estimates of incidence are important to target better pre-
vention, diagnosis and care strategies.
Introduction
HIV epidemic surveillance largely relies on cross-sectional measurements of prevalence, often
by means of representative household surveys. However, for a non-remissible condition with
extended survival time like HIV, instantaneous prevalence reflects the epidemic trajectory
(incidence, mortality and migration) over a significant period prior to the survey. Estimating
HIV incidence—the most sensitive and informative indicator of current epidemiological
trends—therefore poses significant methodological challenges.
The ‘gold standard’ method of directly observing new infections in cohorts of HIV-negative
individuals followed up over time are costly and logistically challenging, and it is difficult to
ensure sufficient population representivity to ensure results can be generalised. Several alterna-
tive approaches have been proposed for estimating HIV incidence, including a ‘synthetic
cohort’ approach—i.e. inferring incidence from the age and/or time structure of prevalence
[1–6], from biomarkers for ‘recent infection’ measured in cross-sectional surveys [7–11], or
using dynamical population models that have been calibrated to survey data [12–15]. No single
method by itself achieves the desired levels of accuracy and precision [16].
In this work we develop a novel hybrid method which uses an ‘optimal’ weighting of, (a) an
implementation of the ‘synthetic cohort’ approach of Mahiane et al. [6]—i.e. interpreting the
age and time structure of prevalence, in conjunction with excess mortality—and (b) an adapta-
tion of the Kassanjee et al. estimator for incidence from biomarkers of recent infection [8] that
takes account of the age structure of recent infection (amongst HIV-positive individuals). The
method of Mahiane et al. relies on the instantaneously exact, fully age- and time-structured,
representation of the dynamical relation of prevalence, excess mortality and incidence. In the
case of a relatively stable epidemic (i.e. relatively slow change in age-specific prevalence over
time), the age structure of prevalence provides fairly precise age-specific incidence estimates.
HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches
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We applied this method to a cross-sectional household survey conducted in a district of
KwaZulu-Natal province (KZN) to estimate the HIV incidence by age and sex in the area at
the time of the survey (2013). For the present analysis we assume stability, but we investigate
the impact of plausible time-gradients of prevalence in the sensitivity analysis. Precision of
incidences estimates is markedly lower for ages over 30, and we therefore report as primary
results incidence over age range 15-29 years.
Methods
Survey design and procedures
The data analysed in this study were obtained from the Mbongolwane and Eshowe HIV
Impact in Population Survey, conducted in 2013 in Mbongolwane, a rural area, and Eshowe,
the main town in the uMlalazi Municipality in KZN, South Africa. A two-stage stratified clus-
tered sampling strategy was used for the selection of households according to the 2011 Census,
which indicated a population of approximately 120,000 at the time of the survey [17]. Individ-
uals aged 15-59 years old living in sampled households, and who provided informed consent,
were enrolled in the study.
The University of Cape Town Human Research Ethics Committee (HREC 461/2012), the
Health Research Committee of the Health Research and Knowledge Management Unit of the
KwaZulu-Natal Department of Health and the Comite´ de Protection de Personnes de Paris in
France approved the study protocol.
Face-to-face interviewer-administered questionnaires were used to collect information on
socio-demographics and sexual history at the sampled household. HIV testing, including pre-
and post-test counselling, was done by certified lay counsellors, on site, using the Determine
Rapid HIV-1/2 Antibody test kit as a screening test followed, in the case of a positive result, by
the Unigold Rapid HIV test kit for confirmation. Venous blood specimens were collected
from all participants who consented. HIV antibody-positivity was determined using the on-
site rapid result, confirmed by laboratory-based ELISA in the case of discordant rapid test
results. Specimens from participants confirmed to be HIV antibody-positive were subjected to
the Sedia Limiting Antigen Avidity EIA (LAg) assay [18], the Bio-Rad Avidity assay [19], as
well as a quantitative viral load, CD4 count and an ARV presence test. Viral load testing was
performed using a NucliSens EasyQ HIV-1 v2.0 assay from Biomerieux. Qualitative testing for
ARV drug levels, including nevirapine, efavirenz and lopinavir, was performed using a LC
MS/MS qualitative assay. In addition, to detect acute infections in antibody-negative partici-
pants, HIV-negative specimens were subjected to pooled Nucleic Acid Amplification Testing
(NAAT) testing (in 5-member pools) using Roche AMPLISCREEN, and specimens from posi-
tive pools tested individually using the Roche CAP/CTM assay.
More detail on the survey has been published elsewhere [17, 20–22].
Estimating incidence using biomarkers for ‘recent’ infection
We used calibration data from the Consortium for the Evaluation and Performance of HIV
Incidence Assays (CEPHIA) to explore a range of recent infection case definitions based on
combinations of LAg normalised optical density (ODn), Bio-Rad Avidity index (AI) and viral
load thresholds, and selected an ‘optimal’ recent infection testing algorithm (RITA) based on
the variance of the incidence estimates produced. The procedures and results are detailed in S1
Appendix. These show that a RITA that defines recent infection as NAT+/Ab− OR Ab+/ODn
< 2.5/AI < 30/VL > 75 achieves a mean duration of recent infection (MDRI, adjusted for the
sensitivity of the screening algorithm) of 217 days (95% CI: 192,244) and a context-specific
HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches
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false-recent rate (FRR) of 0.17% (95% CI: 0.05%,0.35%). We analyse sensitivity to imperfectly-
estimated FRR in S2 Appendix.
This definition of recency was then employed to estimate incidence in the study population,
by age group and sex, using the method of Kassanjee et al. [8]. The well-known Kassanjee et al.
estimator, adapted for use in complex surveys by allowing the use of proportions and their
standard errors, rather than survey counts, is given in Eq 1.
l ¼
PH  ðPRjþ   TÞ
ð1   PHÞ  ðOT   T  TÞ
ð1Þ
where PH is the prevalence of HIV, PR|+ is the proportion of recency tests performed on HIV-
positive participants that produced a ‘recent’ result, OT is the MDRI and T is the FRR, and T is
the chosen time cutoff beyond which a ‘recent’ result is considered ‘falsely recent’ by defini-
tion. Note that the product of PH and PR|+ is the overall prevalence of recency in the sample.
This estimator is implemented in the inctools R package [23]. The documentation of inctools
provides details on estimating the variance of incidence estimates using both delta method and
bootstrapping approaches.
Owing to the small ‘recent infection’ case counts, statistical uncertainty reaches unaccept-
able levels when age groups are small, and we therefore estimated incidence using the conven-
tional approach in 15 to 29 year-olds and 30 to 59 year-olds.
For the purpose of the combined method described below, we further adapted the estimator
for age-dependent prevalence of recent infection, allowing us to estimate highly granular age-
specific incidence using the recent infection biomarker data in the survey. Details are provided
in the section on the combined method.
Estimating age-specific incidence using the Mahiane et al. ‘synthetic
cohort’ method
We employ the incidence estimator of Mahiane et al. [6] to estimate incidence from the age
structure of prevalence. The estimator was derived from the fundamental relationship between
incidence, prevalence and mortality in a non-transient condition—with prevalence viewed as
the accumulated incidence over time, accounting for the removal of prevalent cases from the
population through condition-induced ‘excess’ mortality. This is shown using a simple
dynamical SI-type model, where it is demonstrated that simply rearranging the differential
equations describing change in the state variables for the susceptible and infected groups yields
an estimator for incidence that relies only on prevalence and excess mortality (but critically,
not total mortality). In an age-structured population, this approach yields the incidence esti-
mator in Eq 2.
lða; tÞ ¼
1
1   pða; tÞ

@
@t
pða; tÞ þ
@
@a
pða; tÞ
 
þ dða; tÞ  pða; tÞ ð2Þ
where p(a,t) is age and time-specific prevalence and δ(a,t) is age and time-specific excess
mortality.
In a stable epidemic, where the age structure of prevalence is not changing at a significant
rate in secular time (see Discussion section), the age-structure of prevalence from a single
cross-sectional prevalence survey is informative, and the estimator can be simplified to:
lðaÞ ¼
1
1   pðaÞ

d
dt
pðaÞ þ dðaÞ  pðaÞ ð3Þ
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We obtained age-specific incidence estimates by fitting a regression model for prevalence
as a function of age to finely-grained data (i.e., not using integer ages, but the difference in
days between the birth date and interview date of each participant), using a generalised linear
model with a cubic polynomial in age as predictors and a logit link:
gðpðaÞÞ ¼ b0 þ b1aþ b2a2 þ b3a3 ð4Þ
with g() the logit link function, so that
pðaÞ ¼
1
1þ expð  b0   b1a   b2a2   b3a3Þ
ð5Þ
and
d
da
pðaÞ ¼
expðb0 þ b1aþ b2a2 þ b3a3Þ  ðb1 þ 2b2aþ 3b3a2Þ
ð1þ exp ðb0 þ b1aþ b2a2 þ b3a3ÞÞ
2 ð6Þ
We fit the model, separately for males and females, to data from participants aged 15 to
34 years. This provided us with a continuous function, p(a), for 15 a< 35. We derived, for
each sex, the function for excess mortality, δ(a), from age-specific AIDS mortality estimates
for KwaZulu-Natal province produced by the Thembisa demographic model [24], allowing us
to estimate age-specific incidence, λ(a).
Reproducibility of the incidence estimate at any given age was investigated by bootstrap-
ping the dataset (reproducing the complex sampling frame employed in the survey), refitting
the models and obtaining an incidence estimate for each of the 10,000 resampled datasets. The
standard deviation of the obtained estimates was computed to approximate the standard error,
and the 2.5th and 97.5th percentiles to approximate the 95% confidence interval.
Estimating age-specific incidence using the combined method
In order to estimate age-specific incidence by combining HIV prevalence data and biomarkers
for recent infection, available in the same dataset, we estimated age-specific incidence (and its
variance) using (1) the synthetic cohort method described above, and (2) an adaptation of the
Kassanjee et al. estimator to age-structured recency biomarker data. The adapted estimator is
shown in Eq 7.
lðaÞ ¼
PHðaÞ  ½PRjþðaÞ   T 
½1   PHðaÞ  ðOT   T  TÞ
ð7Þ
where PH(a) is the age-specific prevalence of HIV (estimated as in the previous section), and
PR|+(a) is the age-specific prevalence of recency amongst HIV-positives (described below).
In order to obtain the prevalence of recency as a function of age we fit a generalised linear
regression model with log of age as linear predictor and a complementary log-log link. This
functional form implies an exponential decline in the prevalence of recency with age, which
captures the epidemiologically sensible assumption that at young ages larger proportions of
infections were acquired in the recent past. The model has the functional form:
gðPRðaÞÞ ¼ b0 þ b1 lna ð8Þ
with g() the link function, so that
PRðaÞ ¼ exp ðb0 þ b1 lnaÞ ð9Þ
HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches
PLOS ONE | https://doi.org/10.1371/journal.pone.0203638 September 13, 2018 5 / 16
Owing to the use of prevalence in both estimates, the incidence estimates are necessarily
correlated. We therefore resample the data (replicating the complex sampling frame), fit the
models of PH(a) and PR(a), and at each age of interest, obtain the two incidence estimates, λP
(incidence from age-structured prevalence) and λR (incidence from age-structured recency
amongst positives). We then evaluate, at each age of interest, from 10,000 bootstrap iterations,
the variances and covariance of the two incidence estimates, in the case of λR further incorpo-
rating uncertainty in MDRI and FRR. We then compute a combined incidence estimate using
a weighted average of the two estimates. The implied weighting function, W(a), derived from
the ‘optimal’ weighting factors, Wa (i.e. the weighting factor that minimises variance of the
combined estimate) obtained at each evaluated age, is then convolved with the combined inci-
dence function. At a particular age a, incidence from the combined method is given by Eq 10.
la ¼Wa  lP;a þ ð1   WaÞ  lR;a ð10Þ
with 0Wa 1, and consequently no normalisation to total weight is required. The variance
of the incidence estimate at a given age is obtained from Eq 11.
s2
l
¼W2s2
lP
þ ð1   WÞ2s2
lR
þ 2rslPslRWð1   WÞ ð11Þ
with ρ the Pearson’s correlation coefficient between λP and λR at that age. The value of W that
minimises total variance at the age of interest is obtained from the following formula, derived
by setting Eq 11 to 0 and solving for W:
W ¼
s2
lR
  rslPslR
s2lP þ s
2
lR
  2rslPslR
ð12Þ
The continuous incidence function λ(a) is then obtained by fitting a cubic interpolating
spline (using the method of Forsythe, Malcolm and Moler) to estimated incidence, λa, for all
ages in the range 15 to 35 years, evaluated at steps of 0.25 years.
For comparability with conventional age-group estimates, ‘average incidence’ was esti-
mated in age bins. The integral of the λ(a) function was evaluated over the age range for which
average incidence was sought, and weighted using a weighting function reflecting (a) the sam-
pling density, or (b) the susceptible population density, to obtain average incidence. For popu-
lation weighting, the population by age and sex was obtained from the 2011 Census for
Eshowe and Mbongolwane, and the susceptible population size estimated using prevalence
estimates from the survey data. Susceptible population-weigthted estimates are presented as
primary results.
The unweighted incidence spline function, λ(a) was weighted by a weighting function f(a),
derived from either the sampling density or the susceptible population density, and the integral
evaluated over the age range of interest (a0 to a1) in order to obtain weighted average incidence
over that range, as shown in Eq 13.
I ¼
R a1
a0
lðaÞf ðaÞ da
R a1
a0
f ðaÞ da
ð13Þ
The procedure was performed separately for males and females, and in order to obtain
overall average incidence, these estimates were then further weighted using the weighting
functions for males and females.
HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches
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Defining total weights for the two sexes as WM ¼
R a1
a0
fMðaÞ da and WF ¼
R a1
a0
fFðaÞ da, for
any age interval and weighting function, the total incidence is then given by Eq 14.
ITot ¼
WM  IM þWF  IF
WM þWF
ð14Þ
Confidence intervals were obtained by bootstrapping the data (10,000 iterations), and in
each iteration estimating average incidence.
The source code utilised in this estimation procedure is made available in S1 Code.
Sensitivity analyses
In order to investigate the sensitivity of our analyses to uncertainty in the False-Recent Rate,
we repeated the incidence estimation procedure using a range of FRRs between 0% and 1%.
We further investigated sensitivity of average incidence to the weighting scheme.
The implementation of the method developed in this paper does not take into account
change in prevalence (and incidence) in the time dimension. This is valid when the epidemic
is relatively stable and most of the information is captured in the age structure of prevalence.
In order to investigate sensitivity to possible change over time in age-specific prevalence, we
investigated a number of hypothetical scenarios in which age-specific prevalence is increasing
or decreasing exponentially.
Sensitivity analyses are reported in S2 Appendix.
Results
Conventional analysis of the biomarkers for recent infection (in large age bins) yielded an
overall HIV incidence estimate for individuals aged 15 to 59 years at the time of the survey of
1.60 cases/100 person-years (PY) (95% CI: 1.11,2.16). In males 15-59 the incidence was esti-
mated at 0.71/100PY (0.22,1.25) and in females 15-59 at 2.26/100PY (1.48,3.14). Among indi-
viduals aged 15-29, the main group of interest in this work, overall incidence was estimated at
2.03/100PY (1.37,2.77), for males at 0.89/100PY (0.28,1.58) and for females at 3.05/100PY
(1.87,4.37). These results are presented in Table 1. Smaller age bins do not yield informative
results using the conventional approach, owing the small case counts of recent infections.
By way of comparison, the age-continuous biomarker-based method, which is a key com-
ponent of the combined method, yielded ‘average incidence’ estimates (weighted by suscepti-
ble population density) in individuals aged 15-29 overall of 1.87 cases/100PY (1.31,2.43), in
males of 0.81/100PY (0.22,1.45) and in females of 2.95/100PY (1.98,4.04). The synthetic cohort
method yielded susceptible population-weighted average incidence in individuals aged 15-29
overall of 3.19/100PY (2.83,3.56), in males of 2.00/100PY (1.53,2.46) and in females of 4.39/
100PY (4.00,4.85). Using the combined method, we obtained incidence estimates in individu-
als aged 15-29 of 2.54/100PY (2.07,2.77), in males of 1.26/100PY (0.64,1.49) and in females of
Table 1. Conventional biomarker-based estimates for large age groups.
Age group
years
Males P.E. (95% CI)
cases/100PY
Females P.E. (95% CI)
cases/100PY
Total P.E. (95% CI)
cases/100PY
[15,30) 0.89 (0.28,1.58) 3.05 (1.87,4.37) 2.03 (1.37,2.77)
[30,60) 0.22 (0.00,0.99) 1.06 (0.15,2.04) 0.78 (0.12,1.48)
Overall [15-60) 0.71 (0.22,1.25) 2.26 (1.48,3.14) 1.60 (1.11,2.16)
Implicitly weighted by sampling density.
https://doi.org/10.1371/journal.pone.0203638.t001
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3.83/100PY (3.35,4.37). These results (as well as for five-year age bins) are reported in Tables 2
and 3.
Age-specific estimates using the combined method are shown in the figures. Incidence esti-
mates are presented as continuous functions of age for individuals aged 15-29, with the contri-
butions of the age-continuous biomarker and synthetic cohort methods. Fig 1 shows the
overall results, Fig 2 the estimates for males and Fig 3 the estimates for females. Estimates
become uninformative at ages over 30, owing to greatly increased statistical uncertainty.
Incidence in females rose steeply during the teenage years, from 1.31 cases/100PY
(0.97,1.66) at age 15 to a peak of 4.95/100PY (4.09,5.81) at age 23. Incidence was lower—but
still very high—in women in their late twenties and early 30s, with estimated incidence of 4.50/
100PY (3.07,5.92) at age 30. Uncertainty in the estimates increased with age (with a standard
error of approximately 0.7 at age 30, compared to 0.4 at age 23). Estimates were very imprecise
for ages over 30: at age 35, incidence was estimated at 2.78/100PY, with a standard error of
1.67, resulting in a 95% CI of 0.00,6.06. Age-specific incidence in teenaged males was substan-
tially lower than in females, estimated at 0.32 cases/100PY (0.00,0.65) at age 15, and rising
sharply from the early twenties, peaking at 4.10/100PY (2.75,5.46) at age 30. Incidence in
males aged 23 was estimated at 1.39/100PY (0.95,1.82). Overall incidence estimates reflect the
estimates for males and females so that estimated incidence at age 15 was 0.82 cases/100PY
(0.64,1.00), peaked at 4.47/100PY (3.52,5.41) at age 29, and was 4.42/100PY (3.37,5.47) at
age 30.
Discussion
This study describes a novel hybrid method that allows for reasonably precise estimation of
age-specific incidence up to about age 30 years. It constitutes a significant improvement over
Table 2. ‘Average incidence’ estimates by age group using the biomarker and synthetic cohort methods.
Age-continuous biomarker mothod Synthetic cohort method
Age group
years
Males P.E. (95% CI)
cases/100PY
Females P.E. (95% CI)
cases/100PY
Total P.E. (95% CI)
cases/100PY
Males P.E. (95% CI)
cases/100PY
Females P.E. (95% CI)
cases/100PY
Total P.E. (95% CI)
cases/100PY
[15,20) 0.45 (0.08,0.88) 1.92 (1.02,3.05) 1.20 (0.73,1.78) 0.27 (0.00,0.60) 2.90 (2.30,3.48) 1.61 (1.24,1.92)
[20,25) 0.71 (0.16,1.38) 3.73 (2.41,5.30) 2.20 (1.51,2.92) 1.59 (1.14,2.05) 5.26 (4.53,6.20) 3.40 (2.96,3.91)
[25,30) 1.50 (0.40,2.73) 3.62 (2.04,5.38) 2.52 (1.52,3.45) 5.09 (3.36,6.64) 5.70 (4.33,7.30) 5.38 (4.23,6.65)
[30,35) 2.02 (0.24,4.50) 2.66 (0.71,5.47) 2.33 (0.99,4.30) 4.07 (0.00,11.18) 8.53 (2.29,16.43) 6.20 (2.47,11.29)
[15,30) 0.81 (0.22,1.45) 2.95 (1.98,4.04) 1.87 (1.31,2.43) 2.00 (1.53,2.46) 4.39 (4.00,4.85) 3.19 (2.83,3.56)
Weighted by susceptible population density.
https://doi.org/10.1371/journal.pone.0203638.t002
Table 3. ‘Average incidence’ estimates by age group using the combined method.
Age group
years
Males P.E. (95% CI)
cases/100PY
Females P.E. (95% CI)
cases/100PY
Total P.E. (95% CI)
cases/100PY
[15,20) 0.36 (0.00,0.61) 2.62 (2.07,3.11) 1.51 (1.13,1.75)
[20,25) 1.22 (0.71,1.49) 4.73 (4.00,5.54) 2.95 (2.46,3.28)
[25,30) 2.64 (1.13,3.26) 4.65 (3.68,5.79) 3.61 (2.48,4.19)
[30,35) 2.76 (0.38,4.79) 3.56 (1.77,6.15) 3.14 (1.38,4.65)
[15,30) 1.26 (0.64,1.49) 3.83 (3.35,4.37) 2.54 (2.07,2.77)
Weighted by susceptible population density.
https://doi.org/10.1371/journal.pone.0203638.t003
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conventional cross-sectional incidence estimation using biomarkers of recent infection, where
small case counts limit informative estimates to large age bins.
We confirm previously-described very high incidence among young women and also
among slightly older young men. A compartmental mathematical model developed by Blaizot
et al. [25] produced similar incidence estimates by sex and age group when calibrated to the
same data [26]. In females, incidence peaked at age 23, and in males at age 30. We have previ-
ously described that young people were more likely to transmit HIV. In the same survey,
among individuals aged 15-19 years and 20-34 years 34% and 35% respectively were unaware
of their HIV status and 66% and 53% were virally unsuppressed; both factors were associated
with higher-risk sexual behaviour [20]. Precise age-specific incidence estimates are important
to identify the age and gender groups most at risk. These findings highlight the need for tar-
geted prevention and HIV testing strategies for girls and young women, as well as men aged 20
to 40 years.
The conventional biomarker-based approach does not allow finely-grained age-specific
incidence estimation, since small case counts (or sample proportions) result in very wide con-
fidence intervals. Even analysis of the data in five-year age bins produce estimates that cannot
be clearly distinguished from zero. Our adapted age-continuous biomarker estimates provide
reasonably reproducible estimates in younger individuals, where the parameterisation of the
prevalence of recent infection (amongst HIV-positive individuals) is likely to be sound. How-
ever, this method would be more challenging to implement in older individuals, where the dis-
tribution of recent infections is more complicated.
Fig 1. HIV incidence by age in males and females aged 15-30, using the synthetic cohort, recency biomarker and combined methods.
https://doi.org/10.1371/journal.pone.0203638.g001
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The synthetic cohort method provides additional information on incidence, and in certain
age ranges is in fact more informative than the biomarker method. As can be seen in the fig-
ures, at younger ages the two estimates are very similar, but diverge at older ages. At younger
ages the synthetic cohort method has greater precision (estimates have lower variance). In
females, the combined estimate is weighted in favour of the synthetic cohort method through-
out the age range 15 to 29, but with more heavily skewed at younger ages (weighting factor of
0.84 at age 15 and 0.54 at age 29), whereas in males the weighting tips towards the biomarker
method at age 25.
The idea of using demographic structure of prevalence data to infer incidence is certainly
not new. Williams et al. [1] developed something very close to the approach we are taking—
the main difference being their proposal (in light of data available at that time) to use age-
averaged rather than age-specific estimates of time dependence of prevalence. We follow the
instantaneously exact, fully age and time-structured, representation of the relation of preva-
lence, mortality and incidence that was introduced in Mahiane et al. [6]. That paper also con-
sidered the previously-published methods of Brunet and Struchiner [2, 3], Hallett et al. [4],
and Brookmeyer and Konikoff [5], all of which were found to have substantial biases, noted to
be the result of their various particular forms of dynamical approximation—essentially using
assumptions of constant prevalence in age and time ranges.
An advantage of the hybrid approach is that it combines both age-specific HIV prevalence
data and biomarker data, thus reducing the risk of bias in HIV incidence estimation. By com-
bining the estimates from the two methods, age-specific incidence can be estimated with sig-
nificantly greater precision than with the biomarker method alone. For example, at age 15 in
Fig 2. HIV incidence by age in males aged 15-30, using the synthetic cohort, recency biomarker and combined methods.
https://doi.org/10.1371/journal.pone.0203638.g002
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females, the standard error on the age-continuous biomarker estimate of 0.91 cases/100PY is
0.42 (i.e. a coefficient of variation of 46%) and the standard error on the weighted average of
1.31/100PY is 0.18 (CoV = 13%). The narrower confidence bounds around the combined
method estimates can be clearly seen in the figures. At certain ages, there is a very substantial
improvement, for example in males aged 22, the CoV on the biomarker estimate is 47%, while
on the combined estimate it is 18%. The precision of the combined method is not greatly
enhanced over that of the synthetic cohort method, but estimates are likely to be more accu-
rate, especially where information on change in the age structure of prevalence over time is
not available, which may bias estimates.
For the recent infection case definition adopted for this analysis we estimated, using
CEPHIA calibration data, a very small context-specific false-recent rate. Unfortunately, the
FRR is also the test property that is hardest to estimate, and where the transferability from cali-
bration data to the surveyed population is most problematic. While we adopted a sophisticated
approach to context adaptation of the test property estimates, these challenges remain. For
present purposes we assumed that the test properties (MDRI and FRR) do not vary with age,
although it is likely that the longer (on average) time-since-infection in older individuals
would impact the FRR and that biological changes in the immune system would impact the
MDRI. In estimating context-specific FRR we make assumptions about the population-level
distribution of times-since-infection, but a lack of data on past incidence precludes a more
nuanced age-specific FRR estimate. This limitation is addressed by means of a sensitivity anal-
ysis with respect to FRR, as reported in S2 Appendix. Given the very low population-level FRR
estimate, it is unlikely that this assumption introduces substantial bias. The sensitivity analyses
Fig 3. HIV incidence by age in females aged 15-30, using the synthetic cohort, recency biomarker and combined methods.
https://doi.org/10.1371/journal.pone.0203638.g003
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indicate that our results are not highly sensitive to the false-recent rate, although it becomes
more so at older ages, where the combined method relies more on the biomarker-based
estimate.
While the use of pooled nucleic acid amplification testing increases the sensitivity of the
screening algorithm, this strategy adds considerably to the cost. Defining NAAT yield (acutely
infected) cases as recently infected also added approximately 15 days to the MDRI of the RITA
[27]. However, we identified only two acute infections, and it is not clear that this strategy is
feasible in most large population-based surveys.
The impact of ART on recency biomarkers is well-established—treated individuals tend to
undergo partial seroreversion resulting in “false” recent classifications. The inclusion of a viral
load threshold in the RITA ameliorates this problem, resulting in a very low FRR, although cal-
ibration data are lacking on treated but virally unsuppressed individuals (see S1 Appendix).
The increasing adoption of early treatment (“Universal Test-and-Treat”) has the potential to
impact the MDRI of RITAs that classify treated (or virally suppressed) individuals as non-
recent, although at the time of this survey, very few (if any) individuals in the study population
would have received ART within two years of infection. The impact of ART on the synthetic
cohort method is likely to be largely innocuous, as long as accurate age-specific excess mortal-
ity estimates are employed. Increasing uptake of early ART would further reduce the already
low excess mortality in young HIV-infected individuals.
A major limitation of this study is that we are analysing data from a single cross-section
survey, providing no information on change in the (age-structured) prevalence over time.
A second survey is planned in the study population, which would allow future analyses to
be conducted that explicitly incorporate change over time. We investigated the sensitivity of
Fig 4. HIV incidence by age in males and females aged 15-35, using the synthetic cohort, recency biomarker and combined methods.
https://doi.org/10.1371/journal.pone.0203638.g004
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our estimates to prevalence changes in time, and found that estimates from the combined
method are not very sensitive to plausible rates of change in prevalence at the time of the sur-
vey. However, if the assumption of a stable epidemic were violated and rapid increases or
declines in prevalence were taking place at the time of the survey, our method would exhibit
significant bias. It would therefore be preferable to explicitly incorporate the time dimension
in the analysis (by using data from serial prevalence surveys) and it is essential that the version
of the method that ignores time is only applied in settings where the assumption of stability is
sound.
Further, estimates become very uncertain at ages over 30 (see Fig 4), resulting in synthetic
cohort, biomarker and combined method estimates with confidence intervals that stretch
from close to zero to very large values. The failure of the method to provide informative esti-
mates at higher ages requires further investigation. This limitation may, in part, reflect the par-
ticular parameterisation of regression models for HIV prevalence and for the prevalence of
‘recent infection’ used in the present analysis.
Conclusion
This analysis demonstrates the value of age-structured prevalence data, when reasonable esti-
mates of excess mortality are available, and that when additional biomarkers of recent infec-
tion are available these can be sensibly incorporated into age-specific incidence estimates.
The novel hybrid method used in this analysis can be extended to allow the analysis of serial
prevalence (and, when available, recent infection) data, without significant further conceptual
development, for maximally informative incidence estimation. Application of this method to
large-scale population-based HIV prevalence surveys is likely to result in improved incidence
surveillance over methods currently in wide use. Reasonably accurate and precise age-specific
estimates of incidence are important to target better prevention, diagnosis and care strategies.
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